Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | NQO1 | P15559 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | POLA1 | P09884 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GLP1R | P43220 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9476338 | 0.81 | ALDH1A1 (0.46) | ALDH1A1CYP3A4HSP90AB1HSP90AA1GAA | |
| SCHEMBL17595014 | 0.79 | ALDH1A1 (0.43) | ALDH1A1CYP3A4GAACA1CA2 | |
| SCHEMBL19782400 | 0.75 | KDM4E (0.41) | ALDH1A1CYP3A4HSP90AB1HSP90AA1KDM4E | |
| SCHEMBL15819694 | 0.75 | CYP3A4 (0.40) | ALDH1A1CYP3A4GAAKDM4EKMT2A | |
| SCHEMBL28158622 | 0.75 | HSP90AA1 (0.33) | HSP90AB1HSP90AA1GAAKDM4ENQO1 | |
| SCHEMBL535658 | 0.70 | ALDH1A1 (0.36) | ALDH1A1CYP3A4HSP90AB1HSP90AA1GAA | |
| SCHEMBL14764510 | 0.70 | KDM4E (0.32) | ALDH1A1HSP90AA1KDM4EKMT2AMAPT | |
| SCHEMBL4188467 | 0.70 | ALDH1A1 (0.37) | ALDH1A1HSP90AB1HSP90AA1KMT2ATDP1 | |
| SCHEMBL30313634 | 0.70 | ALDH1A1 (0.37) | ALDH1A1HSP90AB1HSP90AA1KMT2ATDP1 | |
| SCHEMBL11293369 | 0.69 | POLB (0.43) | ALDH1A1GAAKDM4EKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4694893-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME Therapeutics LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250326748-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12428425-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2025-09-30 | — | — | US | disclosed |
| WO-2025101780-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | OCTANT, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| WO-2025080788-A1 | CCR4 INHIBITORS AND METHODS OF USE THEREOF | RAYTHERA, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2024216229-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC (US) | 2024-10-17 | — | — | WO | disclosed |
| US-20240309003-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| EP-4412617-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME Therapeutics LLC (US) | 2024-08-14 | — | — | EP | disclosed |
| US-20240182477-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. | 2024-06-06 | — | — | US | disclosed |
| WO-2024057013-A1 | NLRP3 MODULATORS | EXSCIENTIA AI LIMITED (GB) | 2024-03-21 | — | — | WO | disclosed |
| US-20050090666-A1 | Process for producing 2,6-dihalogenopurine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1375502-A1 | PROCESS FOR PRODUCING 2,6-DIHALOGENOPURINE | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-20030144508-A1 | Process for producing 2,6-dihalogenopurine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-0255217-B1 | FUSED IMIDAZOHETEROCYCLIC COMPOUNDS | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1992-01-22 | — | — | EP | disclosed |
| US-4948800-A | MUSCLE RELAXANTS; ANTICONVULSANTS; ANXIOLYTIC AGENTS; 3-HYDROXYALKYL-PYRIDO(4,5-B OR-C)IMIDAZOLE COMPOUNDS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1990-08-14 | — | — | US | disclosed |
| US-4914109-A | ANTICONVULSANTS, ANTIANXIETY AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1990-04-03 | — | — | US | disclosed |
| US-4873251-A | MUSCLE RELAXANTS, ANTICONVULSANTS, ANTIANXIETY AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-10-10 | — | — | US | disclosed |
| US-4824951-A | MUSCLE RELAXANTS, ANTICONVULSANTS, ANXIOLYTIC AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-04-25 | — | — | US | disclosed |
| US-4772600-A | MUSCLE RELAXANTS, ANTICONVULSANTS, ANXIOLYTIC | A. H. ROBINS COMPANY, INC. (US) | 1988-09-20 | — | — | US | disclosed |
| EP-0255217-A1 | Fused imidazoheterocyclic compounds | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1988-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428425-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | ALDH1A1 2654/4885CYP3A4 1273/4885HSP90AB1 2919/4885 |
| US-20240309003-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | ALDH1A1 2654/4885CYP3A4 1273/4885HSP90AB1 2919/4885 |
| US-20240182477-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | ALDH1A1 2654/4885CYP3A4 1273/4885HSP90AB1 2919/4885 |
| US-20250326748-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | ALDH1A1 3559/4885CYP3A4 3937/4885HSP90AB1 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.